Clinical Study

A Phase II/III Randomized Trial Of Veliparib Or Placebo In Combination With Adjuvant Temozolomide In Newly Diagnosed Glioblastoma With Mgmt Promoter Hypermethylation

Posted Date: Sep 7, 2017

  • Investigator: Rekha Chaudhary
  • Co-Investigator: Rekha Chaudhary
  • Specialties: Hematology/Oncology, Oncology, Cancer, Neurology
  • Type of Study: Drug

The purpose of this study is to compare the effects, good or bad of the usual treatment (temozolomide) with or without the addition of the investigational drug veliparib for people whose brain tumors show a change in a small region of DNA (gene) called O6-methylguanine methyltransferase (MGMT). Your tumor showed this change, called MGMT methylation, and researchers want to see if veliparib combined with temozolomide has an effect in your particular type of brain tumor. Veliparib is not approved by the FDA for any type of cancer at this time.


To Be Eligible To Participate, Patients Must Have A Type Of Brain Tumor Called A Glioblastoma Multiforme (Gbm) And Have Completed The First Part Of Treatment With Radiation Combined With The Chemotherapy Drug Temozolomide (Tmz).


Cancer, Glioblastoma, Mgmt Promoter Hypermethylation, A071102, Brain Tumor

For More Information:

Uc Cancer Institute

  • Search Clinical Studies

  • Research in the News

    Enhanced Recovery Program for Colorectal Surgery Patients Reduces Costs

    A standardized protocol for managing patients for the duration of colorectaloperations not only improved clinical outcomes, but also it significantlyreduced hospital costs.